Prescription medication · DPP-4 Inhibitor
alogliptin
Also sold as Nesina.
Data updated 2026-05-15
- 3,393
- FDA reportsLightly reported
- 7
- InteractionsFew interactions
- 62% less
- Generic vs brandBig savings
- $13.10
- Brand price (NADAC)
What the data shows
alogliptin (Nesina) is a prescription DPP-4 Inhibitor, among the least-reported drugs the FDA tracks (3,393 FDA reports), whose generic runs roughly half the brand price or less (62% less).
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$13.10/unit
Generic Price
$5.02/unit
Generic Savings
62%
Generic Available
Yes (0 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Information not available.
Common side effects
Upper respiratory tract infection, Common cold, Diarrhea
Key warnings
No specific warnings noted. Always follow your prescriber's instructions.
Side Effects (from patient reports)
Based on 3,393 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for alogliptin, by number of reports
- Diarrhoea
Diarrhoea
134 reports
- Nausea
Nausea
124 reports
- Vomiting
Vomiting
110 reports
- Acute Kidney Injury
Acute Kidney Injury
101 reports
- Pemphigoid
Pemphigoid
101 reports
- Malaise
Malaise
93 reports
- Rash
Rash
92 reports
- Blood Glucose Increased
Blood Glucose Increased
86 reports
- Dyspnoea
Dyspnoea
84 reports
- Decreased Appetite
Decreased Appetite
82 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for alogliptin each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where alogliptin sits
alogliptin has more FDA adverse-event reports than 20% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is alogliptin; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 3,393 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2011–2025.
Total Reports
3,393
Reports Mentioning Death
356
10.5% of reports — not proof of cause
Hospitalization Reports
1,564
Top Indication
Type 2 Diabetes Mellitus
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | DIARRHOEA | 134 |
| 2 | NAUSEA | 124 |
| 3 | VOMITING | 110 |
| 4 | ACUTE KIDNEY INJURY | 101 |
| 5 | PEMPHIGOID | 101 |
| 6 | MALAISE | 93 |
| 7 | RASH | 92 |
| 8 | BLOOD GLUCOSE INCREASED | 86 |
| 9 | DYSPNOEA | 84 |
| 10 | DECREASED APPETITE | 82 |
| 11 | PNEUMONIA | 82 |
| 12 | PYREXIA | 78 |
| 13 | DIZZINESS | 77 |
| 14 | PRURITUS | 76 |
| 16 | CEREBRAL INFARCTION | 72 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Known Drug Interactions
Examples: Topiramate, zonisamide, acetazolamide or dichlorphenamide Drugs that Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .
Mechanism: Topiramate can stop your kidneys from clearing metformin properly, which may cause the drug to build up to dangerous levels.
Examples: Topiramate, zonisamide, acetazolamide or dichlorphenamide Drugs that Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .
Mechanism: Zonisamide interferes with how your kidneys remove metformin from your body, which can increase the risk of a serious condition called lactic acidosis.
( 7 ) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. ( 7 ) Alcohol can potentiate the effect of metformin on lactate metabolism. ( 7 ) Metformin HCl Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.
Mechanism: These two drugs work in different ways to lower blood sugar. When taken together, they have an additive effect to help control blood sugar levels.
( 7 ) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin on lactate metabolism.
Mechanism: Dolutegravir can slow down how quickly the body removes metformin. This can cause metformin to build up in the blood, increasing the risk of side effects.
( 7 ) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin on lactate metabolism.
Mechanism: Ranolazine can interfere with the body's ability to clear out metformin. This leads to higher levels of metformin in the body.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What are the common side effects of alogliptin?
Does alogliptin interact with other medications?
What drug class is alogliptin?
Is there a generic version of alogliptin?
Related Medications in DPP-4 Inhibitor
Other drugs grouped near alogliptin - same-class peers and common alternatives.
acarbose
Precose
Acarbose is a medicine that helps lower blood sugar levels in people with type 2 diabetes.
Compare with alogliptin →
bromocriptine
Cycloset
Bromocriptine (Cycloset) is a medicine that acts like dopamine in your body.
Compare with alogliptin →
canagliflozin
Invokana
Invokana is a medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Compare with alogliptin →
colesevelam
Welchol
Colesevelam is a medicine that helps lower bad cholesterol (LDL-C) and control blood sugar in adults.
Compare with alogliptin →
dapagliflozin
Farxiga
Dapagliflozin (Farxiga) helps lower blood sugar in adults with type 2 diabetes.
Compare with alogliptin →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for alogliptin: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 3,393.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 10.49%.
- tretinoin Δ 0.05 pts · 7,629 reports · Retinoid (Topical) 10.54%death share
- metronidazole Δ 0.06 pts · 63,731 reports · Nitroimidazole Antibiotic 10.56%death share
- ramipril Δ 0.08 pts · 119,507 reports · ACE Inhibitor 10.57%death share
- nizatidine Δ 0.12 pts · 1,480 reports · H2 Receptor Antagonist 10.61%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on alogliptin
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for alogliptin
The FDA label for alogliptin (sold under brand names such as Nesina) classifies it as a prescription-only medication in the DPP-4 Inhibitor class. Regulatory labeling describes its approved uses and the patient populations studied in pre-market trials. Official labeling lists 7 commonly reported side effects, including Upper respiratory tract infection, Common cold, Diarrhea.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 3,393 voluntary reports. The database also lists 7 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS shows a generic unit cost of $5.02 versus $13.10 for the brand - a 62% generic savings.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: April 11, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages